About burosumab
FGF23-blocking monoclonal antibody
Used for
- Treats X-linked hypophosphatemia in adults and children aged 6 months or older.
- Treats tumor-induced osteomalacia in adults and children aged 2 years or older.
Usual adult dose
X-linked hypophosphatemia: 1 mg/kg under the skin every 4 weeks, maximum 90 mg. Tumor-induced osteomalacia: 0.5 mg/kg every 4 weeks; specialist adjustment may be needed.
Usual dose in children
X-linked hypophosphatemia: from 6 months, 0.8 mg/kg under the skin every 2 weeks, adjusted by blood phosphate. Tumor-induced osteomalacia: from 2 years, specialist dosing.
Common side effects
- Injection-site reactions
- Headache and dizziness
- Muscle or joint pain
- Restless legs syndrome
Important warnings
- Can cause high blood phosphate, increasing kidney calcification risk.
- Blood phosphate and kidney health require monitoring.
- Do not use with oral phosphate or active vitamin D analogues.
- Avoid in severe kidney impairment or when phosphate is normal or high.
Pregnancy
Limited human information; animal studies raise possible fetal risk. Use during pregnancy only when clinically necessary.
Breastfeeding
It is unknown whether burosumab passes into human milk; discuss potential risks with a clinician.
Interactions
- Oral phosphate and active vitamin D analogues can raise phosphate excessively.
- Medicines affecting phosphate levels may require closer monitoring.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.